Every four weeks
The coverage-source ladder increases in four-week steps; not an approved schedule.
Protocol / Research Dosing Guide
Cagrilintide Dosage Guide: Trial Schedule, Reconstitution and Safety
An evidence-organized cagrilintide reference separating published clinical-trial designs from unapproved research-vial calculations and vendor claims.
Last reviewed September 15, 202621 minute readResearch information only
Level 5 — Randomized human trialsPhase 3 researchNot FDA approved
Cagrilintide Quick Start
Cagrilintide is a long-acting amylin analogue developed for once-weekly subcutaneous research. Randomized trials have evaluated it alone and with semaglutide, but trial parameters are not an approved regimen and vendor vials are not clinical-trial products.
Why researchers care
Appetite, weight, and metabolic research
Class
Long-acting acylated amylin analogue
Route reported
Subcutaneous once weekly in clinical trials
Cycle length
26–68 weeks studied; no approved cycle
Regulatory status
Investigational; not FDA approved
Loading supplier information
Cagrilintide Dosing Protocol and Schedule
The supplied source presents a 0.25-to-2.4 mg weekly titration. Published trials studied several weekly doses, including up to 4.5 mg in Phase 2; the exact ladder shown here is source reported and is not an approved label.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–4 | 0.25 mg weekly | Coverage-source ladder |
| Weeks 5–8 | 0.5 mg weekly | Coverage-source ladder |
| Weeks 9–12 | 1.0 mg weekly | Coverage-source ladder |
| Weeks 13–16 | 1.7 mg weekly | Coverage-source ladder |
| Week 17+ | 2.4 mg weekly | Coverage-source target; not approved |
These values summarize the supplied source and research designs; they are not prescribing instructions or a validated protocol for a research vial.
Cagrilintide Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Cagrilintide Reconstitution Calculator
Vial-format concentration math
Concentration
2.5 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Cagrilintide: Morning or Night?
Which day?
Clinical trials used once-weekly administration; no day of the week is superior.
Morning or evening?
Not established.
With food?
Not applicable to the studied subcutaneous route.
Missed amount?
No FDA-approved cagrilintide label exists; do not treat secondary-source rules as official instructions.
Cagrilintide Route Comparison
| Route | Research context | Evidence limit |
|---|---|---|
| Subcutaneous | Once weekly in human trials | Investigational study administration |
| Oral | Not established | No validated oral exposure regimen |
| Vendor research vial | Commercially listed | Not equivalent to trial material |
| Route conversion | Not established | No interchangeable-route formula |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Cagrilintide Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Reported human half-life | Approximately 159–195 hours | Supports weekly trial design |
| Peak concentration | Not established here | Depends on formulation and study |
| Steady state | Not established for vendor vials | Trial formulation cannot be assumed |
| Long-term accumulation | Not established | No approved-use specification |
Cagrilintide Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous trial | 0.3–4.5 mg | Once weekly for 26 weeks | Randomized Phase 2 | Study design |
| Subcutaneous | 0.25 mg | Weekly, weeks 1–4 | Coverage source | Not approved |
| Subcutaneous | 0.5–1.7 mg | Four-week steps | Coverage source | Not approved |
| Subcutaneous | 2.4 mg | Weekly from week 17 | Coverage source | Not approved |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Cagrilintide Reconstitution Guide
Concentration: 2.5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.25 mg | 0.1 mL | 10 units |
| 0.5 mg | 0.2 mL | 20 units |
| 0.75 mg | 0.3 mL | 30 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Cagrilintide Works
Amylin analogue
Designed to activate amylin receptors involved in satiety and meal-related signaling.
Cagrilintide Human Trials and FDA Status
Current status · verified September 15, 2026
Investigational; not FDA approved
- A 706-participant Phase 2 trial compared weekly cagrilintide doses with placebo and liraglutide over 26 weeks.
- The 4.5 mg Phase 2 group had greater mean weight reduction than placebo, with gastrointestinal and injection-site events commonly reported.
- Phase 3 REDEFINE programs have studied cagrilintide alone and in CagriSema over longer periods.
- Trial formulations, eligibility criteria, titration, and oversight are integral to those results.
- Cagrilintide is not FDA approved as a standalone medicine.
Who Should Avoid Cagrilintide?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No approved use or established safety
History of severe gastrointestinal motility disorder
Trial eligibility and amylin-class effects require clinical review
Pancreatitis or gallbladder disease
Potential class-related concerns require medical review
Insulin or sulfonylurea use
Hypoglycemia risk may differ with concomitant therapy
Known ingredient sensitivity
Potential allergic risk
Unsupervised research-vial use
Vendor material is not an approved medicine
Cagrilintide Side Effects, Risks and Safety
NauseaHuman trial reported
Important limitation: Common and dose-related in Phase 2.
Injection-site reactionsHuman trial reported
Important limitation: Common in the 4.5 mg Phase 2 group.
Constipation or vomitingHuman trial reported
Important limitation: Gastrointestinal effects occurred.
Pancreatitis or gallbladder eventsPotential concern
Important limitation: Long-term risk remains under study.
Drug interactionsIncomplete
Important limitation: No comprehensive interaction profile.
Multi-year safetyNot established
Important limitation: Development remains ongoing.
Cagrilintide Timeline and Monitoring
26 weeks
Published Phase 2 monotherapy study duration.
68 weeks
Phase 3 endpoint period in REDEFINE programs.
Rest period
Not established; trial completion is not evidence for cycling or restarting.
Cagrilintide Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Weight reduction | Randomized human evidence | Dose-ranging and Phase 3 programs | Investigational, not approved |
| Appetite or satiety | Mechanism-supported human research | Amylin-pathway effects | Individual response varies |
| Glycemic outcomes | Human combination research | Population and co-therapy specific | Not a standalone indication |
| Long-term cardiovascular benefit | Not established | Outcomes research is incomplete | No approved claim |
Cagrilintide Storage and Handling
Unreconstituted vendor vial
No independently verified cagrilintide-vial stability duration was identified.
Prepared vendor vial
A 28–30 day refrigerated window is community/vendor guidance, not a published stability result.
Clinical-trial formulation
Trial handling cannot be generalized to commercial research vials.
Appearance
Visual inspection cannot establish identity, purity, or sterility.
Cagrilintide Troubleshooting
Calculator differs from another chart
Recheck vial mg, liquid mL, target mg, and U-100 conversion.
Trial and source amounts differ
Preserve each study's dose, formulation, population, and duration.
Combination data appear
Do not assign CagriSema outcomes to cagrilintide alone.
Product testing is pending
Do not describe the exact vial as batch verified until current documents are public.
A scheduled amount is missed
No approved cagrilintide missed-dose instruction exists.
Cagrilintide Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Cagrilintide | Amylin analogue | Phase 2/3 human trials | Not approved |
| Pramlintide | Amylin analogue | Approved for specific diabetes use | Different molecule and regimen |
| Semaglutide | GLP-1 receptor agonist | Approved indications | Different mechanism |
| CagriSema | Cagrilintide + semaglutide | Phase 3 research | Combination evidence |
Cagrilintide Frequently Asked Questions
What is cagrilintide?
A long-acting investigational amylin analogue.
Is it FDA approved?
No standalone cagrilintide product is FDA approved.
Does it have human trials?
Yes, randomized Phase 1, 2, and 3 programs exist.
What is its reported half-life?
Approximately seven to eight days in clinical development sources.
Was 4.5 mg studied?
Yes, in a 26-week Phase 2 dose-ranging trial.
Is 2.4 mg an approved dose?
No; it is a research-program target, not an approved label.
Can CagriSema findings be assigned to cagrilintide alone?
No.
Is a rest period established?
No.
Is vendor-vial stability established?
No independent product-specific stability study was identified.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. Cagrilintide protocol coverage source
Coverage and source-reported titration; not an approved label.
Open direct sourceHuman research
2. Once-weekly cagrilintide for weight management
Randomized Phase 2 dose-ranging human trial.
Open direct sourceTrial registry
3. ClinicalTrials.gov cagrilintide studies
Official registry search for current and completed trial records.
Open direct sourceMissing information flagged for review
- Approved indication and regimen: Not established
- Approved missed-dose instructions: Not established
- Vendor-vial bioequivalence: Not established
- Product-specific reconstituted stability: Not established
- Multi-year safety: Not established
- Completed cardiovascular outcomes: Not established
- Comprehensive interaction data: Not established